A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor

Identification

Name
A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
Accession Number
DB02090  (EXPT02835)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 415.5243
Monoisotopic: 415.268235931
Chemical Formula
C20H37N3O6
InChI Key
JLEGVELHGVWFGG-BBWFWOEESA-N
InChI
InChI=1S/C20H37N3O6/c1-14(2)13-16(15(7-6-11-24)19(26)22-28)18(25)21-17-8-4-5-9-23(20(17)27)10-12-29-3/h14-17,24,28H,4-13H2,1-3H3,(H,21,25)(H,22,26)/t15-,16+,17-/m0/s1
IUPAC Name
(2S,3R)-N-hydroxy-2-(3-hydroxypropyl)-N'-[(3S)-1-(2-methoxyethyl)-2-oxoazepan-3-yl]-3-(2-methylpropyl)butanediamide
SMILES
[H][[email protected]@](CCCO)(C(=O)NO)[[email protected]@]([H])(CC(C)C)C(=O)N[[email protected]@]1([H])CCCCN(CCOC)C1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UStromelysin-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
17754156
PubChem Substance
46508659
ChemSpider
16744190
HET
S80
PDB Entries
1biw

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.58 mg/mLALOGPS
logP0.76ALOGPS
logP0.056ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)8.86ChemAxon
pKa (Strongest Basic)0.079ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area128.2 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity108.5 m3·mol-1ChemAxon
Polarizability44.53 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7248
Blood Brain Barrier-0.5411
Caco-2 permeable-0.6697
P-glycoprotein substrateSubstrate0.8321
P-glycoprotein inhibitor IInhibitor0.7127
P-glycoprotein inhibitor IINon-inhibitor0.7434
Renal organic cation transporterNon-inhibitor0.924
CYP450 2C9 substrateNon-substrate0.8399
CYP450 2D6 substrateNon-substrate0.8042
CYP450 3A4 substrateSubstrate0.6233
CYP450 1A2 substrateNon-inhibitor0.9005
CYP450 2C9 inhibitorNon-inhibitor0.847
CYP450 2D6 inhibitorNon-inhibitor0.8892
CYP450 2C19 inhibitorNon-inhibitor0.8383
CYP450 3A4 inhibitorNon-inhibitor0.8748
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9974
Ames testNon AMES toxic0.6617
CarcinogenicityNon-carcinogens0.8048
BiodegradationNot ready biodegradable0.9178
Rat acute toxicity2.4682 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9753
hERG inhibition (predictor II)Non-inhibitor0.5638
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-alpha amino acids and derivatives
Alternative Parents
Caprolactams / Azepanes / N-acyl amines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Hydroxamic acids / Dialkyl ethers / Azacyclic compounds / Primary alcohols / Organopnictogen compounds
show 4 more
Substituents
N-acyl-alpha amino acid or derivatives / Caprolactam / Azepane / Fatty amide / Fatty acyl / N-acyl-amine / Tertiary carboxylic acid amide / Carboxamide group / Hydroxamic acid / Lactam
show 16 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Details
1. Stromelysin-1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase.
Gene Name
MMP3
Uniprot ID
P08254
Uniprot Name
Stromelysin-1
Molecular Weight
53976.84 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 14:53